UK Guide · Updated August 2026 · Reviewed by our superintendent pharmacist
The trial data is clear: stopping Mounjaro or Wegovy usually means regaining weight. Here's what the evidence actually shows, and how a planned taper gives you the best chance of keeping results.
The short answer
Most people regain weight after stopping a GLP-1 medicine — trials show around 60–75% of the weight lost returns within a year or so, because appetite signalling reverts once the drug clears your system, not because of failure or willpower. You can't eliminate that risk, but you can reduce it: taper the dose gradually rather than stopping abruptly, build resistance training and higher protein intake into your routine before you reduce the dose, and treat stopping as a planned decision with your pharmacist rather than something that happens because you ran out or got bored of injecting. For many people, staying on a low maintenance dose long-term — rather than stopping altogether — is the option that actually holds the result.
Mounjaro (tirzepatide) and Wegovy (semaglutide) work by mimicking gut hormones that tell your brain you're full and quieten constant thoughts about food — often called "food noise". That effect is pharmacological, not permanent: once the medicine clears your system, usually within four to five weeks depending on the drug and dose, appetite signalling reverts towards how it was before treatment. Your stomach also empties food faster again once the drug wears off, so the same portion feels less filling.
Neither medicine causes physical dependence or a withdrawal syndrome in the way that term is used for addictive substances — there's no rebound illness from stopping. What comes back is appetite, not a drug reaction. That distinction matters for how you plan the stop, which we cover below.
Both medicines have been tested specifically for what happens when treatment stops — trial participants were randomised to continue or switch to placebo after an initial run-in period.
| Trial | Continued on treatment | Switched to placebo |
|---|---|---|
| STEP 1 extension (semaglutide, 1 yr off treatment) | n/a — off-treatment arm only | Regained two-thirds of weight lost |
| STEP 4 (semaglutide, weeks 20–68) | Further −7.9% | Regained +6.9% |
| SURMOUNT-4 (tirzepatide, weeks 36–88) | Further −5.5% (89.5% kept ≥80% of loss) | Regained +14.0% (only 16.6% kept ≥80% of loss) |
| 2026 meta-regression, 6 RCTs (both drugs, 1 yr off) | — | ~60% of lost weight regained on average |
The 2026 systematic review also modelled the longer-term trajectory: weight regain slows over time and is projected to plateau at around 75% of what was lost, with a "half-life" of about 23 weeks — so roughly half of the eventual regain happens in the first five to six months after stopping. Cardiometabolic gains (blood pressure, blood sugar, cholesterol) tend to reverse alongside the weight in every trial that measured them.
On the NHS, NICE's technology appraisals set the rules: semaglutide (TA875) and tirzepatide (TA1026) are funded for a maximum of 2 years through specialist weight-management services, with an earlier stopping rule if less than 5% of starting weight has been lost after 6 months on the highest tolerated dose. As a private pharmacy we aren't bound by that NHS funding cap, so we're not forced to stop a treatment that's working well for you at the 2-year mark — but the same underlying question is worth asking regularly: is this still the right treatment, at the right dose, for where you are now?
Good reasons to consider stopping include reaching a personal weight target and wanting to test maintenance without medicine, persistent side effects that outweigh the benefit (see our week-by-week side-effects guide before assuming a dose reduction won't fix it), planning a pregnancy, or cost. Given the regain data above, "I've hit my goal" is often better answered by dropping to a lower maintenance dose than by stopping outright — see our plateau guide for why continuing at maintenance is usually the better default once the scales settle.
Neither medicine has a single mandated taper schedule, and stopping abruptly isn't dangerous — there's no physical withdrawal to manage. But NICE's own practical guide for prescribers recommends that, once a personal weight target has been reached, discontinuing tirzepatide is discussed as a shared decision and carried out gradually — reducing by 2.5 mg at a time over a number of months, rather than stopping in one step.
We apply the same pragmatic principle to semaglutide, where no equivalent formal taper protocol exists: step down one licensed dose level, hold it for four to six weeks, and review weight, appetite and how you're managing before deciding whether to step down again, hold at a low maintenance dose indefinitely, or stop completely. Every step is agreed and monitored face-to-face — we don't support unsupervised dose-splitting or "microdosing" as a way to self-taper; read why on our microdosing page.
You can't out-exercise the appetite change that comes with stopping, but you can blunt it. A body that has kept more muscle burns more calories at rest, which narrows the gap that regain fills. Aim for 1.2–1.6 g of protein per kg of body weight a day and resistance training two to three times a week — ideally started well before you reduce the dose, not after. Our food and muscle guide covers exactly how to structure this.
Beyond the gym, the habits worth locking in before you taper are the boring ones that matter most: a consistent protein-forward breakfast, planning meals rather than reacting to returning hunger, and weighing in weekly so any regain is caught and discussed at a few hundred grams, not several kilograms.
Until recently the honest answer was “we think a lower dose helps, but nobody has tested it properly”. That changed in May 2026, when The Lancet published SURMOUNT-MAINTAIN — the first randomised trial built specifically around this question. People who had reached their weight loss on the maximum tolerated dose of tirzepatide (10 or 15 mg) over 60 weeks were then randomised to carry on at that dose, step down to 5 mg, or switch to placebo, and followed to week 112.
| Stayed on 10–15 mg | Stepped down to 5 mg | Switched to placebo | |
|---|---|---|---|
| Weight vs starting point at week 112 | About 22% below | About 17% below | About 10% below |
| Share of the loss held | Essentially all of it | Around 70% | A minority of it |
| Regained half or more of what they lost | Roughly 1 in 12 | Roughly 1 in 4 | Roughly 2 in 3 |
| Monthly cost at our pharmacy | Highest | Lower | Nil |
| Side effects | Unchanged | Usually milder | Resolve |
This is the single most useful piece of evidence we have for anyone facing the cost question. It says a reduced dose is not a token gesture — it held roughly seven-tenths of the result — while also being clear that it is not the same as staying put. Whether a lower maintenance dose is right for you is a clinical decision made with your prescriber, not something to trial on your own, and these were trial averages rather than a promise. If cost is the pressure, it is worth pricing a step-down before deciding to stop: someone holding on 5 mg Mounjaro rather than 15 mg pays £190 instead of £300 a month here. Full pricing is on our treatments page.
A post hoc analysis of SURMOUNT-4, published in JAMA Internal Medicine in November 2025, grouped people by how much weight they regained after tirzepatide was withdrawn and tracked their cardiometabolic markers alongside it. The improvements reversed roughly in proportion to the regain: systolic blood pressure rose by about 6.8 to 10.4 mmHg and HbA1c by 0.14% to 0.35% across the regain groups, with the steepest changes in those who regained the most. The STEP 1 extension reported the same direction of travel for semaglutide, with most cardiometabolic gains drifting back towards baseline a year after the last injection.
If you started treatment partly for blood pressure, blood sugar or cholesterol, it is worth building a blood pressure check and, where relevant, blood tests into the first few months after stopping, rather than assuming the benefit banked itself. We can do the blood pressure check here at the counter during a review.
Regaining some weight after stopping doesn't mean the treatment failed or that you've undone the benefit entirely — most trial participants who stopped still ended up lighter than where they started. If the regain is faster or larger than you expected, book a review rather than restarting on your own: your pharmacist can check whether a lower maintenance dose, a return to full dose, or a fresh look at diet and activity is the right next step, using the same face-to-face suitability assessment as when you started.
WeightGone UK is a GPhC-registered pharmacy (reg. 1118728) in Timperley, Altrincham, serving Sale, Hale, Stretford, Wythenshawe and the wider Greater Manchester area. Coming off treatment is planned the same way starting it was — face-to-face, weighed on the same scales, with a pharmacist who already knows your history rather than a form on a screen.
Sources
Published 24 August 2026. Written and clinically reviewed by the WeightGone UK pharmacy team. This article is information, not a prescription — suitability, dose changes and any decision to stop, step down or restart treatment are always confirmed face-to-face with a GPhC-registered pharmacist. Trial results are averages and individual results vary.
Most people regain some weight, and often a lot of it. In the STEP 1 trial extension, participants regained two-thirds of their lost weight within a year of stopping semaglutide 2.4 mg. A 2026 systematic review pooling six withdrawal trials found around 60% of the weight lost on treatment came back within a year, with modelling suggesting regain eventually levels off at roughly three-quarters of what was lost. It isn't inevitable for everyone, but it's the average outcome — which is why stopping should be planned, not drifted into.
In the SURMOUNT-4 trial, people who'd lost 20.9% of their body weight on tirzepatide and then switched to placebo regained an average of 14 percentage points over the following year — 82% of them regained a quarter or more of what they'd lost. In the STEP 4 trial, semaglutide continuers lost a further 7.9% while the placebo group regained 6.9% over the same 48 weeks. The pattern is consistent across both medicines: stopping reverses much, though rarely all, of the benefit.
Faster than most people expect, then it slows. The 2026 meta-regression put the half-life of weight regain at around 23 weeks — meaning roughly half of the eventual regain happens in the first five to six months off treatment, before the rate tails off. This matches what we see in clinic: appetite and portion sizes start creeping back within a few weeks, well before the scales show the full picture.
There's no single mandated protocol, and neither medicine causes physical dependence or withdrawal symptoms in the addiction sense — so stopping isn't dangerous. But NICE's own practical guide for tirzepatide suggests reducing the dose by 2.5 mg at a time over a number of months rather than stopping abruptly, once a personalised weight target has been reached, as a shared decision between patient and prescriber. We take the same pragmatic approach with semaglutide: step down one dose level, hold it for four to six weeks, and reassess before going further.
That rule applies to NHS-funded treatment specifically. NICE's technology appraisals for semaglutide (TA875) and tirzepatide (TA1026) cap NHS specialist weight-management prescribing at 2 years, and set a rule to stop earlier if less than 5% of starting weight has been lost after 6 months on the highest tolerated dose. As a private pharmacy we aren't bound by the NHS funding cap, but the same clinical logic applies: treatment should keep being reviewed against your goals, not continued or stopped on autopilot.
They reduce it, but the trial data suggests they rarely prevent it completely, because the medicines change hunger signalling in a way lifestyle changes alone don't fully replace once the drug clears your system. That said, protecting muscle with adequate protein and resistance training before and during any dose reduction gives you a metabolic advantage — a body that has kept more muscle burns more at rest, which blunts the regain even if it doesn't stop it outright.
For most people planning to come off, a gradual step-down gives your appetite and habits time to adjust in stages rather than all at once, and lets your pharmacist catch problems early. There is now trial evidence behind it: in SURMOUNT-MAINTAIN, published in The Lancet in May 2026, people who stepped down from 10 or 15 mg tirzepatide to 5 mg held roughly 70% of their weight loss at week 112, ending around 17% below their starting weight, compared with about 22% for those who stayed on the full dose and around 10% for those switched to placebo. If you're stopping because of side effects rather than reaching a goal, an abrupt stop is reasonable and safe — there's no withdrawal reaction to manage. Either way, this is a decision to make with your pharmacist at a face-to-face review, not alone.
We wouldn't recommend unsupervised dose-splitting or 'microdosing' as a way to taper. It hasn't been studied in trials, the MHRA doesn't support off-license dosing strategies, and splitting doses yourself can introduce contamination and dosing-accuracy risks. The licensed dose steps already give you a structured way to reduce gradually under supervision — see our full explainer on microdosing for why we don't offer it unsupervised.
Medically reviewed by Muhammad Adnan, GPhC-registered Superintendent Pharmacist · Last updated June 2026.
This article is general information and isn't a substitute for personal medical advice. Your pharmacist will assess what's right for you at a face-to-face consultation. More health advice · Book a consultation.
WeightGone